Want to see COGT full AI Analyst Report?
Top Page
Cogent Biosciences
(NASDAQ:COGT)
Select Model
Select Model
Rating:50Neutral
Price Target:
$42.00
▲(14.13% Upside)
Action:Reiterated
Date:08/11/26
Overall score is held back primarily by weak financial performance (pre-revenue, widening losses, and heavy cash burn with rising debt). Technicals are moderately supportive with price above key moving averages and positive MACD, while valuation is difficult to justify on earnings due to a negative P/E and no dividend yield. Governance-related corporate events are positive but secondary to the funding and burn-rate risk.
Positive Factors
Focused precision-medicine pipeline
Cogent’s concentrated precision-medicine pipeline targeting KIT-driven diseases and small-molecule therapeutics focuses R&D on genetically defined patient populations. This specialization can improve trial design, speed patient selection, and create a defensible niche with clearer regulatory paths if clinical data are positive.
Negative Factors
No product revenue
As a pre‑commercial biotech with no product revenue and widening net losses, Cogent remains fully dependent on external financing. Persistent losses increase the frequency and size of required financings, heightening dilution risk and making long‑term program execution contingent on successful trials or deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused precision-medicine pipeline
Cogent’s concentrated precision-medicine pipeline targeting KIT-driven diseases and small-molecule therapeutics focuses R&D on genetically defined patient populations. This specialization can improve trial design, speed patient selection, and create a defensible niche with clearer regulatory paths if clinical data are positive.
Read all positive factors
Cogent Biosciences (COGT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.37B
Dividend YieldN/A
Average Volume (3M)2.84M
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth4.92%
CountryUS
Employees258
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.31
Shares Outstanding173,524,980
10 Day Avg. Volume1,953,092
30 Day Avg. Volume2,837,687
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)8.99
Price to Sales (P/S)0.00
P/FCF Ratio-21.50
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$53.86Price Target Upside46.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$7.31M
Cogent Biosciences Business Overview & Revenue Model
Company Description
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered...
How the Company Makes Money
Cogent Biosciences is a clinical-stage biotechnology company and does not have publicly known, material product sales; as a result, it has historically not generated recurring revenue from commercialized therapies. Its cash inflows are primarily f...
Cogent Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.33M | -4.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -372.86M | -321.26M | -251.51M | -188.82M | -130.37M | -70.28M |
| Net Income | -377.18M | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M |
Balance Sheet | ||||||
| Total Assets | 834.55M | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M |
| Cash, Cash Equivalents and Short-Term Investments | 792.30M | 900.76M | 287.08M | 265.71M | 259.28M | 219.68M |
| Total Debt | 244.26M | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M |
| Total Liabilities | 302.16M | 301.24M | 71.61M | 55.63M | 45.08M | 17.91M |
| Stockholders Equity | 532.39M | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M |
Cash Flow | ||||||
| Free Cash Flow | -309.24M | -266.00M | -208.36M | -156.42M | -125.50M | -60.48M |
| Operating Cash Flow | -307.55M | -264.44M | -207.79M | -153.62M | -118.64M | -58.76M |
| Investing Cash Flow | -499.99M | -399.53M | 38.28M | -97.82M | -124.72M | -1.72M |
| Financing Cash Flow | 861.53M | 878.23M | 214.45M | 163.54M | 163.56M | 37.98M |
Cogent Biosciences Technical Analysis
Neutral
36.80
Price Trends
38.64
Negative
36.64
Positive
36.92
Positive
Market Momentum
-0.71
Positive
45.36
Neutral
50.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Neutral. The current price of 36.8 is below the 20-day moving average (MA) of 38.63, below the 50-day MA of 38.64, and below the 200-day MA of 36.92, indicating a neutral trend. The MACD of -0.71 indicates Positive momentum. The RSI at 45.36 is Neutral, neither overbought nor oversold. The STOCH value of 50.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COGT.
Cogent Biosciences Risk Analysis
Cogent Biosciences disclosed 61 risk factors in its most recent earnings report. Cogent Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cogent Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $9.80B | 122.73 | 12.03% | ― | 34.81% | 44.59% | |
62 Neutral | $6.31B | -56.89 | -20.57% | ― | ― | -76.46% | |
56 Neutral | $7.70B | -36.18 | -80.48% | ― | 53.51% | -3.31% | |
53 Neutral | $6.07B | -146.55 | 21.72% | ― | -42.84% | -106.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $6.37B | -16.06 | -72.57% | ― | ― | 4.92% | |
47 Neutral | $6.40B | -6.85 | -410.20% | ― | 44.02% | -1101.02% |
* Healthcare Sector Average
COGT
Cogent Biosciences
37.09
25.01
207.04%
PTCT
PTC Therapeutics
71.81
22.02
44.23%
PTGX
Protagonist Therapeutics
149.50
91.36
157.14%
RYTM
Rhythm Pharmaceuticals
112.53
8.30
7.96%
MIRM
Mirum Pharmaceuticals
99.75
24.22
32.07%
BLTE
Belite Bio, Inc. ADR
157.01
92.50
143.39%
Cogent Biosciences Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Cogent Biosciences Announces $400 Million ATM Offering
Neutral
Aug 10, 2026
On August 10, 2026, Cogent Biosciences filed a prospectus supplement with the U.S. Securities and Exchange Commission to enable the sale of up to $400 million in common stock under an existing at-the-market Sales Agreement with Guggenheim Securiti...
Executive/Board ChangesShareholder Meetings
Cogent Biosciences Shareholders Back Board, Governance Proposals
Positive
Jun 11, 2026
At its recent Annual Meeting, Cogent Biosciences shareholders elected all three director nominees, Chris Cain, Ph.D., Arlene Morris and Todd Shegog, reflecting broad investor support for the company’s current leadership and strategic directi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.